APA (7th ed.) Citation

M, G., O, B., V, B., R, F., D, G., V, L., . . . J, C. (2020). TR1801-ADC: A highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors. Molecular oncology, 14(1), 54. https://doi.org/10.1002/1878-0261.12600

Chicago Style (17th ed.) Citation

M, Gymnopoulos, et al. "TR1801-ADC: A Highly Potent CMet Antibody-drug Conjugate with High Activity in Patient-derived Xenograft Models of Solid Tumors." Molecular Oncology 14, no. 1 (2020): 54. https://doi.org/10.1002/1878-0261.12600.

MLA (9th ed.) Citation

M, Gymnopoulos, et al. "TR1801-ADC: A Highly Potent CMet Antibody-drug Conjugate with High Activity in Patient-derived Xenograft Models of Solid Tumors." Molecular Oncology, vol. 14, no. 1, 2020, p. 54, https://doi.org/10.1002/1878-0261.12600.